- Home
- PROK
PROK
ProKidney Corp.
as of 02-20-2026 4:00pm EST
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Upcoming Earnings Alert:
Get ready for potential market movements as ProKidney Corp. (PROK) prepares to release earnings report on 21 Feb 2026.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WINSTON-SALEM |
| Market Cap: | 331.2M | IPO Year: | 2021 |
| Target Price: | $7.40 | AVG Volume (30 days): | 844.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $7.13 | Next Earning Date: | 02-21-2026 |
| Revenue: | $76,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1010.19% | Revenue Growth (next year): | -68.57% |
| P/E Ratio: | -9.54 | Index: | N/A |
| Free Cash Flow: | -155860000.0 | FCF Growth: | N/A |
AI-Powered PROK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare PROK vs Leading Stocks
See how PROK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PROK ProKidney Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.